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To the Editor:
Antibiotics are the most commonly prescribed medicines for acutely unwell children worldwide [1]. Many
of these antibiotic prescriptions are issued in a primary care setting [2–4]. Despite this, a robust evidence
base for agent selection in primary care is lacking for many childhood indications, including
community-acquired pneumonia (CAP). In an era of increasing antibiotic resistance, with optimal
antibiotic use being paramount to preserve this precious resource, trials involving ambulatory patients
representative of those seen in primary care are needed to address this gap.
29 randomised controlled trials involving 14188 children with CAP were included in an updated Cochrane
meta-analysis to identify effective antibiotics for this indication [5]. The authors note that 1) robust
head-to-head comparisons of frequently used antibiotic options for otherwise healthy children are lacking
and 2) meta-analysis findings are not likely to be generalisable to settings with low CAP mortality, such as
high-income countries and primary care [5].
There are three key guidance documents that include recommendations about antibiotic therapy for
ambulatory patients in high-income settings: the British Thoracic Society (BTS) and the Infectious Diseases
Society of America (IDSA) guidelines, and the European Society for Paediatric Infectious Diseases (ESPID)
discussion document on CAP. These all recommend amoxicillin, an extended-spectrum penicillin, as
first-line oral treatment for this indication in mild–moderate disease (as often seen in primary care)
regardless of age [6–8]. Both the BTS and IDSA guidelines specify that their recommendations apply only
to otherwise healthy children [6, 7].
Macrolides, amoxicillin/clavulanate and cephalosporins are also noted as potential treatment options by all
three guidelines, with macrolides commonly being indicated for older children with signs and symptoms
compatible with atypical pathogens [6–8]. Amoxicillin/clavulanate and cephalosporins are specifically
recommended for children with incomplete pneumococcal or Haemophilus influenzae type b vaccination
status by ESPID and IDSA. These three antibiotics have a broader spectrum of coverage, and could have
greater adverse effects on the human microbiome and more unwanted effects for treated patients,
including the selection of resistant bacteria [9–11].
In the USA, high (around 20%) but falling rates of cephalosporin use have been observed [2, 3]. In the UK,
penicillins (including amoxicillin/clavulanate) and macrolides are the most commonly prescribed antibiotics
for the treatment of children in primary care [4]. Given the observed variation in ambulatory care antibiotic
prescribing for childhood CAP, selecting the optimal agent remains a key unresolved question, which could
be appropriately addressed in a pragmatic randomised trial. In line with recommendations on research into
CAP management in low-mortality settings, such a trial would need to be designed as a noninferiority trial
with a focus on patient-relevant outcomes [12]. However, such a strategic (and likely large) trial is only of
value if agent selection is indeed an important dilemma for prescribers.
We aimed to determine and compare preferred first-line antibiotic options for treatment of childhood
CAP amongst general practitioners (GPs) and primary care paediatricians (PPs), the main primary care
providers for children in Europe, to assess which comparators may be relevant in a noninferiority trial of
antibiotics for this indication.
A targeted, cross-sectional online survey was carried out amongst 1574 members of the European Academy
of Paediatrics Research in Ambulatory Settings network (EAPRASnet) (www.eapaediatrics.eu) in July 2014.
The survey comprised five focussed questions. It was also distributed during the winter season 2014–2015 to
∼200 GPs through the Platform for European Preparedness Against (Re-emerging) Epidemics (PREPARE)
(www.prepare-europe.eu).
The survey asked respondents to report their first-line antibiotic choices for treatment of CAP in otherwise
healthy children up to 5 years old (younger group) and those >5 years (older group) who can be managed
at home after primary care assessment. Descriptive statistics were calculated using STATA 13.1 (StataCorp,
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College Station, TX, USA). Differences between GPs and PPs as well as regional differences (respondents
grouped according to the United Nations geoscheme for the European region [13]) were evaluated using
χ2 testing.
The EAPRASnet response rate was 46.4% (n=730; 528 PPs, 54 GPs and 148 others) with 163 additional
responses from the PREPARE network (150 GPs, six PPs and seven others), providing data from 738
primary care providers for analysis.
A preference for aminopenicillins or narrow-spectrum penicillins was expressed by 463 (63%) out of 738
respondents for treatment of younger children and by 280 (38%) out of 736 for older children. For older
children, macrolides were frequently prescribed in the first line of treatment (271 (37%) out of 736). The
second most common antibiotic used in the first line for younger children was amoxicillin/clavulanate
(208 (28%) out of 738).
GPs had a somewhat stronger preference for first-line aminopenicillins than PPs (for younger children,
64% versus 55% (p=0.02); for older children, 55% versus 25% (p<0.001)); PPs had a noticeably stronger
preference for first-line macrolides than GPs when treating older children (46% versus 11% (p<0.001)).
Cephalosporins were reported as being used first-line in 2% of younger children and 1% of older children
by GPs, and in 7% of children regardless of age by PPs.
Table 1 shows the responses according to region and practitioner type. A stronger aminopenicillin or
penicillin preference was observed for GPs than for PPs in Eastern and Western Europe for both age
groups, and for treatment of older children among GPs in Southern and Northern Europe. In addition,
substantial regional variations were observed; for example, only 28% of PPs in Eastern Europe preferred
aminopenicillin treatment for younger children compared with 78% in Northern Europe.
Overall, aminopenicillin or penicillin treatment was the preferred option for the majority of children of all
ages in Northern Europe (91% for younger children and 84% for older children) and Western Europe (61%
and 45%, respectively). In Eastern Europe, amoxicillin/clavulanate was most frequently indicated as being
used first-line for younger (45%) and older children (38%). In Southern Europe, aminopenicillins or
penicillins were preferred for younger children (67%) and macrolides for older children (47%). Macrolides
were also the second most commonly reported first-line option for older children in Western Europe (33%).
Our highly focused, rapid survey indicates the level of clinical equipoise amongst primary care physicians
regarding different antibiotic treatment options in childhood CAP. While the survey was distributed to two
research networks, and therefore did not reach the majority of nonresearcher primary care providers, the
participants are practitioners likely to be involved in recruitment into a potential trial. Consequently,
the acceptability of the trial comparators to these practitioners is paramount. Furthermore, it is unlikely
that the children seen by practitioners within these networks differ from children seen by other primary
care providers. Prescribing preferences for children with underlying disease cannot be determined from the
TABLE 1 Comparison of number of general practitioners (GPs) and primary care
paediatricians (PPs) expressing a preference for first-line prescribing of amoxicillin or
narrow-spectrum penicillins to children with community-acquired pneumonia by European
region
Practitioner type Region
Northern Europe Eastern Europe Southern Europe Western Europe
⩽5-year-olds
PP 9 (77.8, 48.0–97.2) 86 (27.9, 18.8–38.7) 323 (66.9, 61.4–72.0) 116 (50.0, 40.6–59.4)
GP 61 (93.4, 84.1–98.2) 41 (51.2, 35.1–67.1) 52 (69.2, 54.9–81.3) 50 (88.0, 75.7–95.5)
p-value 0.168 0.01 0.737 <0.001
>5-year-olds
PP 9 (55.6, 21.2–86.3) 86 (15.1, 8.3–24.5) 323 (30.0, 25.1–35.4) 116 (28.4, 20.5–37.6)
GP 60 (88.3, 77.4–95.2) 40 (32.5, 18.6–49.1) 52 (48.1, 34.0–62.4) 50 (82.0, 68.6–91.4)
p-value 0.030 0.025 0.01 <0.001
Data are presented as n (%, 95% CI) unless otherwise stated. Northern Europe: Denmark, Finland,
Ireland, Lithuania, Norway, Sweden and the UK; Eastern Europe: Albania, the Czech Republic, Hungary,
Romania and Slovakia; Southern Europe: Cyprus, Spain, Greece, Croatia, Israel, Italy, Montenegro, Malta,
Portugal and Slovenia; Western Europe: Austria, Belgium, Switzerland, Germany, France, Luxembourg and
the Netherlands.
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survey, which focused specifically on otherwise healthy children. Additional factors influencing antibiotic
selection, such as immunisation status, were not elicited. The response rate for the EAPRASnet survey was
just below 50%. Given that the survey was open for only 3 weeks and no reminders were sent,
participation was high. However, it is possible that nonrespondents would have indicated different
prescribing preferences. Finally, we were unable to ascertain actual prescribing practices, which may differ
from responses to our survey.
We were able to highlight the heterogeneity of selecting antibiotics for childhood CAP between different
types of clinicians and across different regions of Europe. While both GPs and PPs express an
aminopenicillin preference for CAP treatment of children of all ages, amoxicillin/clavulanate and
macrolides are also frequently prescribed first-line. Potentially reflecting the greater role of atypical
pathogens in older children [7, 8], macrolides were preferred in some settings for children >5 years of age.
Such variation in current practice needs to be considered during the design of international trial protocols;
for example, when considering comparators relevant to front-line clinical practice. Notably, the results
demonstrate the likely inappropriateness of cephalosporins as a childhood CAP trial comparator choice in
Europe, despite being listed as a secondary treatment option in available guidance.
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